Bevacizumab intravitreal syringes recalled for lack of sterility assurance

Plain-English summary

Bevacizumab 1.75 mg/0.07 mL in 0.25 mL syringes for intravitreal use, 0.07 mL total volume, prescription only and for hospital or office use, from RC Outsourcing LLC of Lowellville, Ohio, is being recalled for lack of assurance of sterility.

The recall covers 2,669 syringes from lots 20250708-768A26 (beyond-use date 6 October 2025), 20250715-944DF2 (13 October 2025) and 20250722-55C603 (20 October 2025). The product was distributed nationwide in the United States. The FDA has classified the recall as Class II.

Sterility matters here because the product is injected directly into the eye. The enforcement record describes a loss of sterility assurance rather than confirmed contamination, and reports no injuries.

Facilities holding the affected lots should stop using them and follow the firm's instructions.

The recalled product

Product

Bevacizumab 1.75 mg/0.07 mL - 0.25 mL syringe, Intravitreal, 0.07 mL Total Volume, Rx Only, Hospital/Office Use Only, Refrigerate, RC Outsourcing LLC, Lowellville, OH 44436.

Manufacturer

RC Outsourcing, LLC

Category

Drug — Injectable

Hazard

• sterility-assurance
• infection-risk
• intravitreal
• compounded

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Distribution

Distributed nationwide across the United States.

Related recalls